- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04754854
Réduction de la recirculation sanguine dans l'ECMO veino-veineuse
Réduction de la recirculation sanguine dans l'ECMO veino-veineux grâce à des mesures de dilution par ultrasons (étude de circulation ECMO)
Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.
A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.
ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.
Aperçu de l'étude
Statut
Description détaillée
Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
State of Berlin
-
Berlin, State of Berlin, Allemagne, 13353
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Inclusion Criteria:
- patients aged 18 years or older
- ARDS
- veno-venous ECMO
Exclusion Criteria:
- age < 18 years
- hemodynamic instability during measurement of recirculation
- pregnancy
- inability to obtain patient's consent or consent of legal guardian
La description
Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Successful ECMO blood flow reduction
Délai: Once within the first week after initiation of ECMO therapy
|
Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction |
Once within the first week after initiation of ECMO therapy
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recirculation fraction
Délai: Once within the first week after initiation of ECMO therapy
|
Fraction of blood recirculating through the ECMO circuit |
Once within the first week after initiation of ECMO therapy
|
|
Arterial blood oxygen content
Délai: Once within the first week after initiation of ECMO therapy
|
Arterial blood oxygen content before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal blood Flow
Délai: Once within the first week after initiation of ECMO therapy
|
ECMO Blood Flow before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal gas flow
Délai: Once within the first week after initiation of ECMO therapy
|
ECMO Sweep Gas flow |
Once within the first week after initiation of ECMO therapy
|
|
Length of ECMO therapy
Délai: Daily until the end of ECMO therapy (approximately 14 days)
|
Days on ECMO |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Cannula position and distance
Délai: Once within the first week after initiation of ECMO therapy
|
The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans) |
Once within the first week after initiation of ECMO therapy
|
|
Right heart dysfunction
Délai: Once within the first week after initiation of ECMO therapy
|
Existing echocardiography will be evaluated for possible right heart dysfunction |
Once within the first week after initiation of ECMO therapy
|
|
Length of mechanical ventilation
Délai: Entire duration of the ICU stay (approximately 28 days)
|
Length of mechanical ventilation |
Entire duration of the ICU stay (approximately 28 days)
|
|
Complications of ECMO therapy
Délai: Length of ECMO therapy (approximately 14 days)
|
Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis |
Length of ECMO therapy (approximately 14 days)
|
|
ICU mortality
Délai: Entire duration of the ICU stay (approximately 28 days)
|
ICU mortality |
Entire duration of the ICU stay (approximately 28 days)
|
|
ICU length of stay
Délai: Entire duration of the ICU stay (approximately 28 days)
|
ICU length of stay |
Entire duration of the ICU stay (approximately 28 days)
|
|
Incidence of ICU-acquired organ dysfunctions and complications
Délai: Entire duration of the ICU stay (approximately 28 days)
|
Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections |
Entire duration of the ICU stay (approximately 28 days)
|
|
ECMO blood flow over time
Délai: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO blood and sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
ECMO sweep gas flow over time
Délai: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Mobility at ICU discharge
Délai: Discharge from the ICU (approximately 28 days)
|
Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently) |
Discharge from the ICU (approximately 28 days)
|
|
Weaning level at ICU discharge
Délai: Discharge from the ICU (approximately 28 days)
|
Level of weaning reached at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Status of mechanical ventilation at ICU discharge
Délai: Discharge from the ICU (approximately 28 days)
|
Status of mechanical ventilation at ICU discharge including all relevant settings and parameters |
Discharge from the ICU (approximately 28 days)
|
|
Level of organ dysfunction at ICU discharge
Délai: Discharge from the ICU (approximately 28 days)
|
Sepsis-related Organ Failure Assessment Score at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of consciousness at ICU discharge
Délai: Discharge from the ICU (approximately 28 days)
|
Glasgow Coma Scale at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of disease severity
Délai: Discharge from the ICU (approximately 28 days)
|
Acute Physiology And Chronic Health Evaluation at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Hospital acquired infections related to ECMO therapy
Délai: Entire duration of ECMO therapy
|
Infection/colonisation of the ECMO circuit |
Entire duration of ECMO therapy
|
|
Bleeding and thrombembolic complications of ECMO therapy
Délai: Entire duration of ECMO therapy
|
Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit |
Entire duration of ECMO therapy
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Martin Russ, Dr. med., Charite University Hospital Berlin
- Chercheur principal: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
- Chercheur principal: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
- Chercheur principal: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EA115620
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .